» Articles » PMID: 35779241

Progression of Echocardiographic Parameters and Prognosis in Transthyretin Cardiac Amyloidosis

Abstract

Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed disease. Echocardiography is widely utilized, but studies to confirm the value of echocardiography for tracking changes over time are not available. We sought to describe (i) changes in multiple echocardiographic parameters; (ii) differences in rate of progression of three predominant genotypes; and (iii) the ability of changes in echocardiographic parameters to predict prognosis.

Methods And Results: We prospectively studied 877 ATTR-CM patients attending our centre between 2000 and 2020. Serial echocardiography findings at baseline, 12 months and 24 months were compared with survival. Overall, 565 patients had wild-type ATTR-CM and 312 hereditary ATTR-CM (201 with V122I; 90 with T60A). There was progressive worsening of structural and functional parameters over time, patients with V122I ATTR-CM showing more rapid worsening of left and right ventricular structural and functional parameters compared to both wild-type and T60A ATTR-CM. Among a wide range of echocardiographic analyses, including deformation-based parameters, only worsening in the degree of mitral (MR) and tricuspid regurgitation (TR) at 12- and 24-month assessments was associated with worse prognosis (change at 12 months: MR, hazard ratio 1.43 [95% confidence interval 1.14-1.80], p = 0.002; TR, hazard ratio 1.38 [95% confidence interval 1.10-1.75], p = 0.006). Worsening in MR remained independently associated with poor prognosis after adjusting for known predictors.

Conclusion: In ATTR-CM, echocardiographic parameters progressively worsen over time. Patients with V122I ATTR-CM demonstrate the most rapid deterioration. Worsening of MR and TR were the only parameters associated with mortality, MR remaining independent after adjusting for known predictors.

Citing Articles

Echocardiography and Heart Failure: An Echocardiographic Decision Aid for the Diagnosis and Management of Cardiomyopathies.

Pender A, Lewis-Owona J, Ekiyoyo A, Stoddard M Curr Cardiol Rep. 2025; 27(1):64.

PMID: 40019673 PMC: 11870920. DOI: 10.1007/s11886-025-02194-y.


Advances and challenges in echocardiographic diagnosis and management of cardiac amyloidosis.

Tian Y, Liu H Int J Cardiovasc Imaging. 2025; .

PMID: 40009119 DOI: 10.1007/s10554-025-03362-5.


Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine.

Gonzalez-Lopez E, Maurer M, Garcia-Pavia P Eur Heart J. 2025; 46(11):999-1013.

PMID: 39791537 PMC: 11905746. DOI: 10.1093/eurheartj/ehae811.


Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction.

Achten A, Muller S, Sanders-van Wijk S, van der Meer M, van der Harst P, van Tintelen P Ann Med. 2024; 56(1):2418965.

PMID: 39460551 PMC: 11514392. DOI: 10.1080/07853890.2024.2418965.


Myocardial Mechanics and Valvular and Vascular Abnormalities in Cardiac Amyloidosis.

Nemes A J Clin Med. 2024; 13(15).

PMID: 39124597 PMC: 11313348. DOI: 10.3390/jcm13154330.


References
1.
Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A . Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133(24):2404-12. DOI: 10.1161/CIRCULATIONAHA.116.021612. View

2.
Treibel T, Fontana M, Gilbertson J, Castelletti S, White S, Scully P . Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. Circ Cardiovasc Imaging. 2016; 9(8). DOI: 10.1161/CIRCIMAGING.116.005066. View

3.
Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba M, Lopez-Sainz A, Giannoni A . Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2019; 13(4):909-920. DOI: 10.1016/j.jcmg.2019.10.011. View

4.
Maurer M, Mundayat R, Rapezzi C . Reply: Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis. J Am Coll Cardiol. 2017; 69(6):758-759. DOI: 10.1016/j.jacc.2016.11.047. View

5.
Quarta C, Solomon S, Uraizee I, Kruger J, Longhi S, Ferlito M . Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014; 129(18):1840-9. DOI: 10.1161/CIRCULATIONAHA.113.006242. View